VC-backed Histogenics goes public
Waltham, Mass.-based Histogenics Corp., a regenerative medicine developer, has debuted its IPO after pricing its 5.9 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "HSGX." Cowen and Co., Needham & Co. and Canaccord Genuity are the lead underwriters. Histogenics' backers include Sofinnova Ventures, Split Rock Partners and Altima Partners.
3 December 2014•2 mins read
